Boldly transforming the lives of individuals with rare neurological diseases
boldvision
Science-driven and patient-focused, our mission is to bring treatments to individuals with rare neurological diseases who have little or no treatment options.
boldscience
Our deep understanding of human genetics and cellular function enables us to translate discoveries into meaningful therapies for rare neurological diseases.
boldcommitment
At Ovid, we seek to understand what matters most to individuals with rare diseases and their families. We are committed to address the challenges they face every day.
investor info
Stock quote
NASDAQ: OVID
$7.37
3.22
11.08.20 | 11:38 AM EST
Copyright West LLC. Minimum 15 minutes delayed.
recent insights
- Ovid Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update
- Ovid Therapeutics to Participate at the William Blair Biotech Focus Conference 2020
- Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome
- Ovid Therapeutics and Angelini Pharma Enter into Exclusive License Agreement to Develop, Manufacture and Commercialize OV101 for the Treatment of Angelman Syndrome in Europe
boldpeople
Each team member understands the difference between a drug and a medicine—one is a product, the other changes lives—and that's what brings us together as Ovidians.